Thompson Davis & Co’s Eli Lilly LLY Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $1.44M | Hold |
1,200
| – | – | 0.86% | 19 |
|
|
2026
Q1 | $1.1M | Hold |
1,200
| – | – | 0.74% | 21 |
|
|
2025
Q4 | $1.29M | Sell |
1,200
-1
| -0.1% | -$956 | 0.77% | 20 |
|
|
2025
Q3 | $916K | Sell |
1,201
-336
| -22% | -$250K | 0.57% | 33 |
|
|
2025
Q2 | $1.2M | Sell |
1,537
-65
| -4% | -$50.5K | 0.82% | 19 |
|
|
2025
Q1 | $1.32M | Buy |
1,602
+65
| +4% | +$54.1K | 1.04% | 9 |
|
|
2024
Q4 | $1.19M | Hold |
1,537
| – | – | 0.76% | 18 |
|
|
2024
Q3 | $1.36M | Sell |
1,537
-150
| -9% | -$135K | 1.01% | 12 |
|
|
2024
Q2 | $1.53M | Buy |
1,687
+12
| +0.7% | +$9.6K | 1.32% | 9 |
|
|
2024
Q1 | $1.3M | Sell |
1,675
-40
| -2% | -$28.5K | 0.88% | 10 |
|
|
2023
Q4 | $1,000K | Sell |
1,715
-860
| -33% | -$502K | 0.85% | 14 |
|
|
2023
Q3 | $1.38M | Sell |
2,575
-1,275
| -33% | -$657K | 1.71% | 10 |
|
|
2023
Q2 | $1.81M | Buy |
3,850
+50
| +1% | +$21K | 2.04% | 9 |
|
|
2023
Q1 | $1.3M | Buy |
3,800
+50
| +1% | +$16.9K | 1.7% | 12 |
|
|
2022
Q4 | $1.37M | Buy |
3,750
+50
| +1% | +$17.7K | 1.95% | 8 |
|
|
2022
Q3 | $1.2M | Buy |
3,700
+600
| +19% | +$190K | 1.62% | 8 |
|
|
2022
Q2 | $1M | Buy |
3,100
+1,120
| +57% | +$336K | 1.64% | 12 |
|
|
2022
Q1 | $567K | Buy |
+1,980
| New | +$510K | 0.69% | 29 |
|
|
2018
Q1 | – | Sell |
-100
| Closed | -$8K | – | 677 |
|
|
2017
Q4 | $8K | Sell |
100
-628
| -86% | -$53.4K | 0.02% | 452 |
|
|
2017
Q3 | $62K | Buy |
728
+58
| +9% | +$4.76K | 0.11% | 190 |
|
|
2017
Q2 | $55K | Hold |
670
| – | – | 0.09% | 211 |
|
|
2017
Q1 | $56K | Sell |
670
-6,393
| -91% | -$512K | 0.08% | 234 |
|
|
2016
Q4 | $519K | Buy |
7,063
+6,413
| +987% | +$478K | 0.86% | 17 |
|
|
2016
Q3 | $52K | Hold |
650
| – | – | 0.09% | 230 |
|
|
2016
Q2 | $51K | Buy |
650
+70
| +12% | +$5.27K | 0.08% | 235 |
|
|
2016
Q1 | $42K | Sell |
580
-2,406
| -81% | -$182K | 0.06% | 271 |
|
|
2015
Q4 | $252K | Buy |
2,986
+1,312
| +78% | +$109K | 0.36% | 71 |
|
|
2015
Q3 | $140K | Buy |
1,674
+1,147
| +218% | +$96.8K | 0.2% | 119 |
|
|
2015
Q2 | $44K | Buy |
527
+50
| +10% | +$3.81K | 0.05% | 334 |
|
|
2015
Q1 | $35K | Sell |
477
-391
| -45% | -$27.8K | 0.04% | 377 |
|
|
2014
Q4 | $60K | Buy |
868
+305
| +54% | +$20.6K | 0.07% | 249 |
|
|
2014
Q3 | $37K | Buy |
+563
| New | +$35.6K | 0.05% | 330 |
|
|
2014
Q2 | – | Sell |
-165
| Closed | -$10K | – | 810 |
|
|
2014
Q1 | $10K | Hold |
165
| – | – | 0.02% | 489 |
|
|
2013
Q4 | $8K | Buy |
+165
| New | +$8.26K | 0.01% | 495 |
|
Other funds holding LLY
Thompson Davis & Co's LLY Position: Q2 2026 in Review
Thompson Davis & Co held its Eli Lilly (LLY) position steady in Q2 2026 at 1,200 shares worth $1.44M. The position accounts for 0.86% of the portfolio, ranked #19.
Thompson Davis & Co first reported a position in LLY in Q4 2013 and has held it in 34 quarters since. The position peaked at $1.81M in Q2 2023. 4,602 funds tracked by Wall St. Rank hold LLY as of Q2 2026.
- Thompson Davis & Co held 1,200 shares of Eli Lilly worth $1.44M as of Q2 2026.
- Thompson Davis & Co left its Eli Lilly share count unchanged in Q2 2026.
- Eli Lilly made up 0.86% of Thompson Davis & Co's portfolio in Q2 2026, its #19 holding.
- Thompson Davis & Co first reported a position in Eli Lilly in Q4 2013 and has held it in 34 quarters since.
- Thompson Davis & Co's Eli Lilly position peaked at $1.81M in Q2 2023.
- 4,602 funds tracked by Wall St. Rank held Eli Lilly as of Q2 2026.
Based on Thompson Davis & Co's 13F filing for Q2 2026, filed 29 Jul 2026.